Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) traded down 10% during trading on Wednesday . The company traded as low as $0.51 and last traded at $0.54. 2,418,292 shares changed hands during trading, an increase of 64% from the average session volume of 1,474,978 shares. The stock had previously closed at $0.60.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers purchased a new stake in shares of Ampio Pharmaceuticals in the second quarter valued at $154,000. Valeo Financial Advisors LLC purchased a new stake in shares of Ampio Pharmaceuticals in the second quarter valued at $155,000. Wells Fargo & Company MN lifted its holdings in shares of Ampio Pharmaceuticals by 113.7% in the fourth quarter. Wells Fargo & Company MN now owns 40,671 shares of the specialty pharmaceutical company’s stock valued at $166,000 after purchasing an additional 21,638 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in shares of Ampio Pharmaceuticals in the first quarter valued at $258,000. Finally, Element Capital Management LLC purchased a new stake in shares of Ampio Pharmaceuticals in the first quarter valued at $290,000.
Ampio Pharmaceuticals Company Profile (NYSEAMERICAN:AMPE)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.